上海医药：二羟丙茶碱注射液获批生产

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for its Dihydroxypropyl Theophylline Injection, which is approved for production [1] Group 1: Product Approval - The drug is classified as a Class 3 chemical drug and is indicated for the relief of symptoms in bronchial asthma and asthmatic bronchitis [1] - As of the announcement date, the company has invested approximately 3.14 million yuan in research and development for this product [1] Group 2: Market Potential - According to IQVIA data, the projected hospital procurement amount for this drug type in mainland China is 325 million yuan by 2025 [1] - The company believes that the approval of this product will enhance its market competitiveness and provide experience for future generic drug applications [1] Group 3: Risks - The company acknowledges that there are risks related to sales not meeting expectations due to policy and market factors [1]